Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Alicia Zhang represents clients on a broad range of strategic corporate transactions, including equity and debt capital market offerings, public and private mergers and acquisitions, and financings. She also advises companies on securities law reporting and other governance and compliance matters.

Capital Markets

  • Represented issuers and underwriters in IPOs, registered follow-on equity offerings and at-the-market offering programs, including:
    • BioNTech SE in its $511 million advanced follow-on offering and the related rights offering of American Depositary Shares;
    • the underwriters in multiple public offerings of Repligen Corporation; and
    • the underwriters in the U.S. IPO and global offering of ordinary shares and ADSs of ERYTECH Pharma S.A.
  • Represented issuers and underwriters in public and private offerings of senior and subordinated debt, including:
    • Johnson & Johnson and Bristol-Myers Squibb Company in offerings of investment-grade notes; and
    • the underwriters in offerings of investment-grade notes of Jefferies Group and of The Clorox Company.


  • Represented Oxford Immunotec in its $591 million acquisition by PerkinElmer.
  • Represented Merck in its $2.7 billion acquisition of ArQule Inc.
  • Represented Astellas in its $3 billion acquisition of Audentes Therapeutics, Inc.
  • Represented Mavis Discount Tire in its merger with Express Oil Change & Tire Engineers, a Golden Gate Capital portfolio company, to create one of the largest U.S. automotive service platforms.
  • Represented AstraZeneca in:
    • the spinoff by MedImmune of discovery stage assets to form biotechnology company, Viela Bio; and
    • the sale of U.S. rights to Synagis and profit participation rights to Sobi for $1.5 billion plus contingent payments.
  • Represented Evercore as financial advisor to United Technologies in its $120 billion merger of equals with Raytheon.
  • Represented leading bank as financial advisor to a subsidiary in a cross-border exchange offer by its parent for up to approximately 25% of its share capital, equivalent to $2.9 billion.

Other Matters

  • Advised numerous companies on public company reporting and other governance and compliance matters.
  • Represented LifeArc, a leading U.K.-based medical charity, in its landmark monetization of a portion of its royalty rights in Keytruda for $1.297 billion, the largest single-product royalty monetization ever done by a non-profit.
  • Represented a Minor League Baseball team in a private capital raise from existing investors.

Pro Bono

  • Counseled non-profits, ranging from international organizations to NYC-based entities, in various transactional, corporate governance and compliance matters.
  • Assisted victim of domestic violence in filing a Form I-751 petition (battered spouse waiver) with USCIS to obtain a green card and secure her stay in the United States.
  • Helped Air Force veteran who was sexually assaulted and inequitably discharged under other than honorable conditions receive upgraded discharge status.